<DOC>
	<DOCNO>NCT02675413</DOCNO>
	<brief_summary>This prospective study explore mechanism efficacy dimethyl fumarate ( DMF ) treatment multiple sclerosis ( MS ) . Investigators enroll relapse MS patient begin therapy DMF one-year longitudinal study blood spinal fluid analysis , image clinical study perform identify measure change associate DMF therapy .</brief_summary>
	<brief_title>Mechanisms Action Dimethyl Fumarate ( Tecfidera ) Relapsing MS</brief_title>
	<detailed_description>The emergence Dimethyl Fumarate ( DMF ) oral agent treatment relapse multiple sclerosis ( MS ) potential reduce burden neurologic disability minimize side effect risk associate established therapy . However , present need understand mechanism action DMF . That , yet know whether benefit observe MS patient treat DMF due primarily immunologic anti-inflammatory effect neuroprotective effect , . The main site ( ) DMF action , whether CNS and/or periphery , also know . Dimethyl fumarate believe act centrally enhance nuclear factor erythroid 2 related factor 2 ( Nrf2 ) transcriptional pathway , regulate enzymes counter act oxidative stress . DMF may enhance Nrf2 transcriptional pathway within CNS , unproven . DMF also anti-inflammatory , know inhibit NFB translocation nucleus [ chemokine-induced monocyte chemotaxis . Inhibition NFB could occur systemically , within CNS , . Therefore , investigator intend investigate antioxidant immunologic change within central nervous system ( CNS ) blood relation DMF therapy .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Diagnosis Relapsing MS ( 2010 McDonald Criteria ) Age great equal 18 . Starting treatment dimethyl fumarate ( DMF ) . Enrolled patient either naive disease modify therapy ( DMT ) enrol great equal 30 day last dose prior DMT . If enrolled patient tolerate DMF , replace another subject . All subject serve control . Women Childbearing Potential pregnant , breastfeeding , plan become pregnant breastfeed duration study . Chronic diseases effect laboratory , clinical imaging parameter study : Insulindependent diabetes mellitus , stroke , Alzheimer 's disease , autoimmune disorder rheumatoid arthritis , lupus , neuromyelitis optica , mixed connective disease , sjogren 's disease . Any prior treatment mitoxantrone alemtuzumab . Those undergoing DMT within past 12 month rituximab daclizumab . Patients treat chronic ( monthly ) systemic steroid . Patients treated steroid ( intravenous , intramuscular , oral ACTH ) intent treat MS within 30 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cerebral Spinal Fluid</keyword>
	<keyword>Dimethyl Fumarate</keyword>
	<keyword>Tecfidera</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>Mechanism Action</keyword>
</DOC>